Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | MDK | P21741 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26952022 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL26952018 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL26951999 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL26956358 | 0.96 | MAPK1 (0.56) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL21652358 | 0.94 | MAPK1 (0.52) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL31129278 | 0.94 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL19509488 | 0.94 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL23393761 | 0.94 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL22111993 | 0.94 | MAPK1 (0.65) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL27061877 | 0.94 | MAPK1 (0.62) | MAPK1LGALS3LGALS8LGALS4MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | MAPK1 1688/4885LGALS3 741/4885LGALS8 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.